Nephro-Urology Monthly

Published by: Kowsar

Role of Renal Re-transplantation in ESRD Patients

Alireza Ghadian 1 , * and Mohammad Hossein Nourbala 1
Authors Information
1 Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
Article information
  • Nephro-Urology Monthly: March 01, 2013, 5 (2); 721-2
  • Published Online: March 30, 2013
  • Article Type: Editorial
  • Received: March 2, 2013
  • Accepted: March 11, 2013
  • DOI: 10.5812/numonthly.11155

To Cite: Ghadian A, Nourbala M H. Role of Renal Re-transplantation in ESRD Patients, Nephro-Urol Mon. 2013 ; 5(2):721-2. doi: 10.5812/numonthly.11155.

Copyright © 2013, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Footnotes
References
  • 1. Koch MJ. Considerations in retransplantation of the failed renal allograft recipient. Adv Chronic Kidney Dis. 2006; 13(1): 18-28[DOI][PubMed]
  • 2. Smyth A. End-Stage Renal Disease and Renal Replacement Therapy in older Patients. Nephro-Urol Mon. 2012; 4(2): 425-30
  • 3. Mohammadreza A, Etemadi J, Ghabili K, Ghojazadeh M, Ghafari A, Tayebi Khosroshahi H. Effect of Dialysis Modality on Transplantation Outcome in Living-Donor Renal Transplantation. Nephro-Urol Mon. 2011; 3(4): 285-90
  • 4. Magee JC, Barr ML, Basadonna GP, Johnson MR, Mahadevan S, McBride MA, et al. Repeat organ transplantation in the United States, 1996-2005. Am J Transplant. 2007; 7(5 Pt 2): 1424-33[DOI][PubMed]
  • 5. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant. 2004; 4(8): 1289-95[DOI][PubMed]
  • 6. 2004 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1994-2003. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA; University Renal Research and Education Association, Ann Arbor, MI.
  • 7. Stephanian E, Matas AJ, Mauer SM, Chavers B, Nevins T, Kashtan C, et al. Recurrence of disease in patients retransplanted for focal segmental glomerulosclerosis. Transplantation. 1992; 53(4): 755-7[PubMed]
  • 8. Ramos E, Vincenti F, Lu WX, Shapiro R, Trofe J, Stratta RJ, et al. Retransplantation in patients with graft loss caused by polyoma virus nephropathy. Transplantation. 2004; 77(1): 131-3[PubMed]
  • 9. Meier-Kriesche HU, Port FK, Ojo AO, Rudich SM, Hanson JA, Cibrik DM, et al. Effect of waiting time on renal transplant outcome. Kidney Int. 2000; 58(3): 1311-7
  • 10. Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation. 2002; 74(10): 1377-81[PubMed]
  • 11. Farney AC, Matas AJ, Noreen HJ, Reinsmoen N, Segall M, Schmidt WJ, et al. Does re-exposure to mismatched HLA antigens decrease renal re-transplant allograft survival? Clin Transplant. 1996; 10(2): 147-56[PubMed]
  • 12. Arnold ML, Pei R, Spriewald B, Wassmuth R. Anti-HLA class II antibodies in kidney retransplant patients. Tissue Antigens. 2005; 65(4): 370-8[PubMed]
  • 13. Jordan SC, Vo A, Bunnapradist S, Toyoda M, Peng A, Puliyanda D, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation. 2003; 76(4): 631-6[PubMed]
  • 14. Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation. 2000; 70(6): 887-95
  • 15. Akalin E, Ames S, Sehgal V, Fotino M, Daly L, Murphy B, et al. Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients. Transplantation. 2003; 76(10): 1444-7[PubMed]
  • 16. Gloor JM, Lager DJ, Moore SB, Pineda AA, Fidler ME, Larson TS, et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation. 2003; 75(7): 971-7[PubMed]
  • 17. Pour-Reza-Gholi F, Nafar M, Saeedinia A, Farrokhi F, Firouzan A, Simforoosh N, et al. Kidney retransplantation in comparison with first kidney transplantation. Transplant Proc. 2005; 37(7): 2962-4[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments